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Impaired HDL cholesterol efflux in 
metabolic syndrome is unrelated 
to glucose tolerance status: the 
CODAM study
Wijtske Annema1,2, Arne Dikkers1,  Jan Freark de Boer1, Marleen M. J. van Greevenbroek3,4, 
Carla J. H. van der Kallen3,4, Casper G. Schalkwijk3,4, Coen D. A. Stehouwer3,4, 
Robin P. F. Dullaart5,* & Uwe J. F. Tietge1,*
Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) increase atherosclerotic 
cardiovascular disease risk. Cholesterol efflux capacity (CEC) is a key metric of the anti-atherosclerotic 
functionality of high-density lipoproteins (HDL). The present study aimed to delineate if T2DM and 
MetS cross-sectionally associate with altered CEC in a large high cardiometabolic risk population. CEC 
was determined from THP-1 macrophage foam cells towards apolipoprotein B-depleted plasma from 
552 subjects of the CODAM cohort (288 controls, 126 impaired glucose metabolism [IGM], 138 T2DM). 
MetS was present in 297 participants. CEC was not different between different glucose tolerance 
categories but was lower in MetS (P < 0.001), at least partly attributable to lower HDL cholesterol 
(HDL-C) and apoA-I levels (P < 0.001 for each). Low grade inflammation was increased in IGM, T2DM 
and MetS as determined by a score comprising 8 different biomarkers (P < 0.05-< 0.001; n = 547). CEC 
inversely associated with low-grade inflammation taking account of HDL-C or apoA-I in MetS (P < 0.02), 
but not in subjects without MetS (interaction: P = 0.015). This study demonstrates that IGM and T2DM 
do not impact the HDL CEC function, while efflux is lower in MetS, partly dependent on plasma HDL-C 
levels. Enhanced low-grade inflammation in MetS may conceivably impair CEC even independent of 
HDL-C and apoA-I.
It is well recognized that both type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MetS) confer a 
substantial increase in the risk of atherosclerotic cardiovascular disease (CVD)1–4. Increased CVD risk in these 
conditions is at least in part related to low plasma levels of HDL cholesterol (HDL-C)4,5, in line with the adverse 
impact of low HDL-C in general population studies6,7. More recently, a shift in concept has been proposed sug-
gesting that impaired HDL function rather than low HDL-C per se may explain HDL-associated risk in these 
conditions8,9. Indeed, among other important HDL functions, its ability to stimulate cellular cholesterol efflux 
may predict presence10 and future risk11,12 of CVD, even independent of HDL-C levels per se.
In the context of HDL function cholesterol efflux represents a key metric9,13. Cholesterol efflux comprises most 
relevantly the mobilization of cholesterol from macrophage foam cells and is the first step in the atheroprotec-
tive reverse cholesterol transport (RCT) pathway13,14. Thus far, variable changes in the cholesterol efflux capac-
ity of HDL from T2DM patients have been reported. While some found decreased efflux15–19, others reported 
unchanged20 or even increased21 HDL efflux capacity in T2DM. However, such studies have mostly been carried 
out in relatively small and selected groups of T2DM patients, and it is still unclear whether altered HDL glyca-
tion due to hyperglycemia adversely affects its ability to promote cholesterol efflux16,21–23. Of further importance, 
enhanced low-grade systemic inflammation is a well known feature of T2DM and MetS24. In turn, inflammation 
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is thought to be a pathophysiologically important determinant of an impaired efflux functionality of HDL and 
subsequently also reduced RCT25,26.
The aim of the present study was (i) to assess in a large cohort of well-characterized subjects whether the 
degree of glucose tolerance impacts on the cholesterol efflux capacity and (ii) to evaluate potential factors deter-
mining such changes.
Results
Five hundred fifty two subjects from the CODAM cohort participated in the present study, of whom 288 had 
normal glucose metabolism (NGM), 126 impaired glucose metabolism (IGM) and 138 T2DM. The respective 
clinical and laboratory characteristics according to glucose tolerance status are shown in Table 1. T2DM subjects 
were slightly older compared to NGM subjects, had a higher body mass index (BMI) and were classified with 
MetS more frequently. A positive history of CVD was most prevalent in T2DM subjects. T2DM subjects also had 
a higher blood pressure, and used antihypertensive medication as well as glucose lowering drugs more frequently. 
Plasma triglycerides were highest, whereas HDL cholesterol and apolipoprotein (apo) A-I levels were lowest in 
T2DM. The low-grade inflammation score was highest in T2DM and lowest in NGM subjects. Of note, choles-
terol efflux capacity did not differ significantly among the glucose tolerance categories (Table 1). There was also 
no difference in cholesterol efflux capacity between glucose tolerance categories after adjustment for age and sex 
(P > 0.19; data not shown). Additionally, cholesterol efflux capacity was not different in NGM subjects (n = 288; 
1.35 ± 0.30) vs. subjects with IGM or T2DM combined (n = 264; 1.32 ± 0.29, P = 0.31).
When the participants were categorized according to the presence and absence of MetS, individuals with the 
MetS expectedly had higher blood pressure, BMI and waist circumference, more frequently used antihypertensive 
drugs, and had a poorer glycemic status (Table 2). Prevalent CVD and use of lipid-modifying medication was 
more frequent in participants with MetS. As expected, MetS subjects had higher triglycerides and apoB levels as 
well as lower HDL-C and apoA-I levels. The low-grade inflammation score was also higher in MetS. Notably, the 







(n = 138) P-value
Age (years) 59 ± 7 60 ± 7 61 ± 6b 0.005
Sex (men/women) 173/115 75/51 91/47 0.45
MetS (yes/no) 92/196 87/39 118/20 < 0.001
Systolic blood pressure (mm Hg) 135 ± 18 143 ± 18c 148 ± 19c < 0.001
Diastolic blood pressure (mm Hg) 80 ± 8 84 ± 9c 85 ± 10c < 0.001
Waist circumference (cm) 96 ± 11 101 ± 12c 105 ± 12c,e < 0.001
BMI (kg/m2) 27.5 ± 3.9 28.9 ± 4.3b 30.3 ± 4.7c,d < 0.001
Current smoking (yes/no/unknown) 60/222/6 25/99/2 26/108/4 0.94
Alcohol consumption (gram/day) 9 (2–23) 9 (1–23) 8 (1–21) 0.61
Cardiovascular disease (yes/no) 69/219 35/91 53/85a,d 0.008
Glucose lowering therapy (yes/no)* 0/288 3/123 68/70c,f < 0.001
Lipid-modifying therapy (yes/no) 46/242 25/101 35/103 0.069
Antihypertensive therapy (yes/no) 84/204 52/74b 80/58c < 0.001
Glucose (mmol/l) 5.3 ± 0.4 5.9 ± 0.5c 7.9 ± 1.8c,f < 0.001
HbA1c (%) 5.6 ± 0.4 5.8 ± 0.4a 6.8 ± 1.1c,f < 0.001
Total cholesterol (mmol/l) 5.22 ± 0.90 5.30 ± 0.93 5.18 ± 1.20 0.58
Non-HDL cholesterol (mmol/l) 3.94 ± 0.94 4.13 ± 0.95 4.12 ± 1.21 0.11
LDL cholesterol (mmol/l) 3.35 ± 0.87 3.37 ± 0.85 3.16 ± 0.87 0.084
HDL cholesterol (mmol/l) 1.27 ± 0.36 1.16 ± 0.34b 1.06 ± 0.29c,d < 0.001
Triglycerides (mmol/l) 1.20 (0.90–1.60) 1.60 (1.10–2.20) 1.80 (1.20–2.40)c,d < 0.001
ApoA-I (g/l) 1.48 ± 0.25 1.45 ± 0.24 1.39 ± 0.22c 0.002
ApoB (g/l) 1.10 ± 0.24 1.16 ± 0.24 1.14 ± 0.26 0.14
Low-grade inflammation score 
(Z-score) − 0.19 ± 0.98 0.08 ± 0.93
a 0.33 ± 1.01c < 0.001
Cholesterol efflux capacity 1.35 ± 0.30 1.34 ± 0.30 1.31 ± 0.29 0.42
Table 1. Clinical characteristics, plasma glucose, glycated hemoglobin (HbA1c), plasma lipids, 
apolipoproteins (apos), low-grade inflammation score and cholesterol efflux in 552 subjects according 
to glucose metabolism status (normal glucose metabolism [NGM], impaired glucose metabolism [IGM] 
and Type 2 diabetes mellitus [T2DM]). Data are given as mean ± SD or median (interquartile range). Apo, 
apolipoprotein; BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high density lipoproteins; LDL, low 
density lipoproteins; MetS, metabolic syndrome. Inflammation markers were available in 287 NGM, 126 IGM 
and 134 T2DM subjects. Low-grade inflammation score is expressed in Z-score of the whole study population. 
* Insulin was used in 12 T2DM subjects. P-value by ANOVA or chi-square test. aP < 0.05 from NGM; bP < 0.01 
from NGM; cP < 0.001 from NGM; dP < 0.05 from IGM; eP < 0.01 from IGM; fP < 0.001 from IGM.
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In the whole study population, cholesterol efflux capacity was lower in men than in women (1.30 ± 0.28 vs. 
1.38 ± 0.31, respectively, P = 0.002), and in current smokers than in non-smokers (1.27 ± 0.28 vs. 1.35 ± 0.30, 
respectively, P = 0.014); these differences disappeared after adjustment for HDL cholesterol (P = 0.93 and 
P = 0.18, respectively). Cholesterol efflux capacity was not significantly different between subjects with and with-
out a history of CVD (P = 0.27), subjects using and not using glucose-lowering drugs (P = 0.17), lipid-modifying 
drugs (P = 0.07) or antihypertensive medication (P = 0.22). Also when dividing the participants according to 
MetS and prevalent CVD, cholesterol efflux capacity did not differ between the respective groups according to 
CVD status (Supplementary Table 1).
Given sex-dependent differences in cholesterol efflux capacity, we carried out sex-adjusted regression analyses 
to determine the relationships of cholesterol efflux capacity with clinical and biochemical variables. There was 
a strong positive correlation of cholesterol efflux capacity with HDL cholesterol and apoA-I in the whole study 
population (Table 3). Similar correlations were observed in the separate glucose tolerance groups, and in subjects 
with and without MetS (interactions: P > 0.33 for all). Cholesterol efflux capacity was positively related to alcohol 
intake in the whole group and in IGM, T2DM and MetS subjects separately. Cholesterol efflux was unrelated to 
systolic blood pressure, waist circumference, non-HDL cholesterol, triglycerides, plasma glucose and HbA1c 
(Table 3). In all subjects combined, as well as in individuals with either T2DM or MetS, cholesterol efflux capacity 
negatively correlated with the low-grade inflammation score (Table 3). Such a relationship was neither observed 
in NGM and IGM subjects, nor in subjects without MetS.
We subsequently tested whether cholesterol efflux capacity was determined by the presence of MetS taking 
account of glucose tolerance status. In age- and sex-adjusted multivariable linear regression analysis, cholesterol 
efflux capacity was negatively related to MetS independent of glucose tolerance status (Table 4, model 1). This 
relationship remained statistically significant after additional adjustment for clinical covariates (Table 4, model 2). 
This analysis confirmed that there was no significant association of cholesterol efflux capacity with glucose tol-
erance status.
We next determined the extent to which cholesterol efflux capacity was independently associated with HDL 
cholesterol, apoA-I and low-grade inflammation in all subjects combined, as well as in NGM, IGM and T2DM 
subjects, and in subjects with and without MetS separately. Cholesterol efflux capacity was positively related to 
No MetS  
(n = 255)
MetS  
(n = 297) P-value
Age (years) 59 ± 7 60 ± 7 0.033
Sex (men/women) 150/105 189/108 0.28
Glucose metabolism status  
(NGM/IGM/T2DM) 196/39/20 92/87/118 < 0.001
Systolic blood pressure (mm Hg) 135 ± 20 145 ± 17 < 0.001
Diastolic blood pressure (mm Hg) 79 ± 9 84 ± 9 < 0.001
Waist circumference (cm) 93 ± 10 105 ± 11 < 0.001
BMI (kg/m2) 26.5 ± 3.4 30.3 ± 4.3 < 0.001
Current smoking (yes/no/unknown) 46/202/7 65/227/5 0.40
Alcohol consumption (gram/day) 10 (3–25) 7 (1–20) 0.46
Cardiovascular disease (yes/no) 51/204 106/191 < 0.001
Glucose lowering drugs (yes/no)* 8/247 63/234 0.001
Lipid-modifying drugs (yes/no) 31/224 75/222 < 0.001
Antihypertensive drugs (yes/no) 65/190 151/148 < 0.001
Glucose (mmol/l) 5.4 ± 0.8 6.6 ± 1.7 < 0.001
HbA1c (%) 5.7 ± 0.5 6.2 ± 0.9 < 0.001
Total cholesterol (mmol/l) 5.14 ± 0.92 5.30 ± 1.04 0.066
Non-HDL cholesterol (mmol/l) 3.75 ± 0.94 4.27 ± 1.02 < 0.001
LDL cholesterol (mmol/l) 3.25 ± 0.87 3.36 ± 0.86 0.15
HDL cholesterol (mmol/l) 1.39 ± 0.34 1.02 ± 0.25 < 0.001
Triglycerides (mmol/l) 1.00 (0.80–1.40) 1.90 (1.40–2.20) < 0.001
ApoA-I (g/l) 1.55 ± 0.24 1.37 ± 0.21 < 0.001
ApoB (g/l) 1.06 ± 0.23 1.19 ± 0.24 < 0.001
Low-grade inflammation score (Z-score) − 0.30 ± 0.93 0.26 ± 0.99 < 0.001
Cholesterol efflux capacity 1.38 ± 0.30 1.29 ± 0.28 < 0.001
Table 2. Clinical characteristics, plasma glucose, glycated hemoglobin (HbA1c), plasma lipids, 
apolipoproteins (apos), inflammation marker score and cholesterol efflux in 552 subjects according to 
metabolic syndrome (MetS) classification. Data are given as mean ± SD or median (interquartile range). 
Apo, apolipoprotein; NGM, normal glucose metabolism; IGM, impaired glucose metabolism; T2DM, type 2 
diabetes mellitus; BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high density lipoproteins; LDL, 
low density lipoproteins. Inflammation markers were available in 293 subjects with MetS and in 254 subjects 
without MetS. Low-grade inflammation score is expressed in Z-score of the whole study population. * Insulin 
was used in 4 subjects without MetS and in 8 subjects with MetS.
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HDL cholesterol and - in parallel analyses - to apoA-I in the whole study population and similarly in the three 
glucose tolerance groups (Supplementary Table 2). These robust relationships were not substantially altered after 
further adjustment for clinical covariates. In these multivariable regression analyses, a relationship of choles-
terol efflux capacity with the low-grade inflammation score was virtually absent in NGM subjects. In T2DM 
subjects, cholesterol efflux capacity tended to be inversely associated with the low-grade inflammation score 
(Supplementary Table 2). When similar analyses were performed in subjects with and without MetS separately, 
cholesterol efflux capacity was observed to be independently and inversely associated with the low-grade inflam-
mation score in subjects with MetS, but not in subjects without MetS (Table 5; interaction: P = 0.015). Finally, 
we assessed the possible contribution of the individual inflammation markers to cholesterol efflux capacity in 
MetS subjects. In age-, sex- and HDL cholesterol adjusted analyses, cholesterol efflux capacity was independently 
and inversely associated with either haptoglobin, ceruloplasmin, serum amyloid A (SAA) and high-sensitivity 
C-reactive protein (hs-CRP) (P < 0.03 for each), but not with the other inflammation markers (P > 0.15 for 
each) (data not shown). Similar associations were found upon controlling for apoA-I instead of HDL cholesterol 
(data not shown). Combined these data demonstrate that low-grade inflammation in MetS patients may confer 
decreased cholesterol efflux independent of plasma HDL-C levels.
Discussion
The present cross-sectional study investigated the impact of glucose tolerance status and the presence of MetS on a 
key functional metric of HDL, namely cholesterol efflux capacity, in a large cohort of clinically well-characterized 
Caucasian subjects selected for high cardiometabolic risk. Our results demonstrate that impaired glucose metab-
olism or established T2DM do not translate into a decreased cholesterol efflux capacity. On the other hand, 
the presence of MetS was associated with diminished cholesterol efflux capacity, which largely coincided with 













Age 0.035 0.088 − 0.063 0.101 0.038 0.069
Systolic blood pressure 0.024 0.082 − 0.067 0.106 0.049 0.0.95
Alcohol consumption 0.129* * 0.008 0.268* * 0.178* 0.034 0.191* 
Waist circumference − 0.034 − 0.007 − 0.033 − 0.010 0.026 0.077
Glucose − 0.014 − 0.075 0.039 0.100 0.046 0.062
HbA1c − 0.040 − 0.030 − 0.094 0.013 0.050 − 0.010
Non-HDL cholesterol 0.026 0.016 0.003 0.053 0.041 0.095
HDL cholesterol 0.367* * * 0.372* * * 0.420* * * 0.301* * * 0.365* * * 0.317* * * 
Triglycerides − 0.048 − 0.056 − 0.122 0.032 − 0.023 0.096
ApoA-I 0.382* * * 0.365* * * 0.378* * * 0.401* * * 0.339* * * 0.368* * * 
ApoB − 0.017 − 0.034 − 0.045 0.035 0.011 0.037
Low-grade inflammation score − 0.125* * − 0.075 − 0.139 − 0.187* 0.009 − 0.162* * 
Table 3.  Relationships of cholesterol efflux capacity with clinical variables, metabolic syndrome (MetS) 
components, apolipoproteins (apos) and low-grade inflammation score in 552 subjects according to 
glucose metabolism status (normal glucose metabolism [NGM], impaired glucose metabolism [IGM] 
and Type 2 diabetes mellitus [T2DM]) and MetS classification. Sex-adjusted partial correlation coefficients 
are shown. Apo, apolipopotein; HDL, high density lipoproteins; HbA1c, glycated hemoglobin. Inflammation 
markers were available in 547 subjects. Triglycerides are log transformed. * P < 0.05; * * P ≤ 0.01; * * * P ≤ 0.001.
Model 1 Model 2
β P-value β P-value
Age 0.047 0.27 0.044 0.32
Sex (men vs. women) − 0.124 0.003 − 0.168 < 0.001
Glucose tolerance category
 IGM vs. NGM 0.037 0.43 0.026 0.57
 T2DM vs. NGM 0.019 0.70 0.022 0.71
MetS (yes/no) − 0.169 < 0.001 − 0.150 0.002
Table 4. Multivariable linear regression analyses demonstrating relationships of cholesterol efflux with 
glucose metabolism status (normal glucose metabolism [NGM], impaired glucose metabolism [IGM] 
and Type 2 diabetes mellitus [T2DM]) and metabolic syndrome (MetS) in 552 subjects. β : standardized 
regression coefficient. Model 1: adjusted for age and sex. Model 2: additionally adjusted for current 
smoking, alcohol consumption, cardiovascular disease, glucose lowering drugs, lipid modifying drugs and 
antihypertensive medication.
www.nature.com/scientificreports/
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low-grade systemic inflammation in decreasing cholesterol efflux in MetS subjects, even independent of plasma 
HDL-C and apoA-I levels.
The impact of impaired glucose tolerance and T2DM on cholesterol efflux towards plasma/serum or isolated 
HDL is not fully clear. Thus far, mostly in smaller sized studies, T2DM was variably associated with changes in 
the cholesterol efflux capacity of HDL. Thereby, on the one hand reduced cholesterol efflux capacity was reported 
using a wide range of cell systems and extracellular acceptors, specifically LpA-I particles in an adipocyte cell 
line15, whole plasma or serum in Fu5AH hepatoma cells17,19, HDL3 in mouse peritoneal macrophages16, or serum 
in transfected cell systems to specifically evaluate SR-BI- and ABCG1-mediated efflux18. However, in a system 
using Fu5AH cells efflux towards plasma from T2DM patients was unchanged compared with control subjects 
with similar HDL cholesterol levels20. On the other hand, with THP-1 macrophages, as also used in our present 
study, increased efflux rates towards whole plasma, apoB-depleted plasma and HDL isolated by ultracentrifuga-
tion were seen in T2DM patients than in controls21. A separate approach reported increased cholesterol efflux 
in T2DM using whole plasma and human skin fibroblasts, but only in hypertriglyceridemic subjects27, whereas 
cholesterol efflux was unchanged in MetS subjects28. Another study confirmed greater efflux rates in hypertriglyc-
eridemic compared with normotriglyceridemic patients using apoB-depleted plasma in BHK cells29. However, in 
our study comprising a large number of subjects with various degrees of glucose tolerance and wide variation in 
plasma triglyceride levels no association of efflux with plasma triglyceride levels were discernable. The reason for 
these experimental discrepancies is incompletely understood. It might conceivably be attributed to the different 
cholesterol acceptor systems used as well as the different cell lines used as cholesterol donors. In the interpretation 
of our study it should also be noted that metabolic control was in general adequate in the studied T2DM subjects, 
making that no conclusions can be drawn for efflux in the context of more severe hyperglycemia. It is important 
to point out that no gold standard is currently agreed upon for cholesterol efflux assays and that there is even no 
consensus on a preferred method to isolate HDL9. In our view, for relevance to CVD it is preferable to use for such 
studies a macrophage cell line, such as THP-1 or J77410, and apoB-depleted plasma10 or isolated HDL to optimally 
discern HDL efflux functionality. One advantage of apoB-depleted plasma is that it still contains preβ -HDL, the 
major acceptor for ABCA1-mediated efflux9. On the other hand, HDL isolated by e.g. ultracentrifugation does 
not contain plasma components such as albumin that could potentially affect efflux. Furthermore, for the clinical 
consequences of diabetes also the effect of the disease on macrophages should be taken into account, since very 
high glucose concentrations can adversely affect the activity of known efflux transporters30,31.
Two smaller scale studies are also available on efflux in MetS patients32,33. One reported greater efflux capacity 
in 25 overweight MetS patients with insulin resistance compared to 22 overweight MetS subjects without insulin 
resistance33. In this study, however, no healthy controls were included and, of note, efflux to whole plasma was 
measured. In addition, although THP-1 cells were employed, these were, in contrast to our study, not loaded with 
modified LDL to induce foam cells. Further the THP-1 cells were treated with an LXR agonist which shifts efflux 
strongly to ABCA1, the transporter mostly responsible for efflux towards preβ -HDL, which was significantly 
higher in the insulin resistant subjects. The other study compared 35 MetS patients and 15 healthy controls using 
apoB-depleted serum and a non-macrophage cell line (BHK) transfected to express ABCA1 and ABCG132. MetS 
patients had significantly higher ABCA1-mediated efflux related to the higher preβ -HDL levels in these patients. 
Serum has the additional disadvantage that to form incubations at room temperature for 20–30 min are required, 
a time during which subtantial HDL remodeling can occur9. Thus, the smaller study size and methodological 
differences likely account for the different results in comparison to our work.
Model 1 Model 2 Model 3 Model 4
β P-value β P-value β P-value β P-value
(A) MetS (n = 293)
Age 0.053 0.35 0.049 0.40 0.076 0.17 0.067 0.24
Sex (men vs. women) − 0.029 0.63 − 0.084 0.20 − 0.003 0.96 − 0.048 0.46
HDL cholesterol 0.305 < 0.001 0.295 < 0.001
ApoA-I 0.363 < 0.001 0.356 < 0.001
Low-grade inflammation score − 0.144 0.013 − 0.156 0.007 − 0.144 0.010 − 0.151 0.009
(B) no MetS (n = 254)
Age − 0.006 0.92 0.002 0.97 − 0.009 0.88 − 0.006 0.92
Sex (men vs. women) 0.040 0.55 0.042 0.56 0.023 0.73 0.033 0.66
HDL cholesterol 0.414 < 0.001 0.411 < 0.001
ApoA-I 0.375 < 0.001 0.376 < 0.001
Low-grade inflammation score 0.079 0.197 0.105 0.096 0.045 0.46 0.069 0.28
Table 5. Multivariable linear regression analyses demonstrating relationships of cholesterol efflux with 
high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I) and low-grade inflammation score 
in 293 subjects with metabolic syndrome (MetS) (A) and in 254 subjects without MetS (B). β : standardized 
regression coefficient. Models 1 include: age and sex, HDL cholesterol and low-grade inflammation score. 
Models 2: additionally adjusted for current smoking, alcohol consumption, cardiovascular disease, glucose 
lowering drugs, lipid modifying drugs and antihypertensive medication. Models 3 include: age and sex, apoA-I 
and low-grade inflammation score. Models 4: additionally adjusted for current smoking, alcohol consumption, 
cardiovascular disease, glucose lowering drugs, lipid modifying drugs and antihypertensive medication.
www.nature.com/scientificreports/
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A potentially important finding of our study is the inverse association between cholesterol efflux capacity and 
low-grade inflammation, which was particularly prominent in the context of T2DM and MetS. Inflammation 
is a condition associated with an impaired efflux function in animal models and humans14,25, and resolution of 
inflammation results in improved efflux25,34. Our current data imply that the efficiency of HDL cholesterol efflux 
capacity might be more strongly related to low-grade inflammation than to hyperglycemia per se. Over time, we 
have identified several metabolic parameters in the CODAM study that are related to low grade inflammation and 
insulin resistance. Some of those can be perceived to be able to affect HDL functionality and, as such, contribute 
to the increased cardiometabolic burden in the MetS. Such metabolic parameters include, for instance, circulating 
complement components35, which may be carried on HDL particles. However, we measured complement compo-
nents in plasma, not on HDL. Likewise, we showed that iron metabolism is cross-sectionally and longitudinally 
associated with insulin resistance36 and might theoretically affect HDL functionality, although the biological rel-
evance remains to be established37.
Of note, out of the 8 biomarkers combined in the inflammation score in our study specifically the 
hepatocyte-derived acute phase proteins haptoglobin, ceruloplasmin, SAA and hs-CRP were negatively correlated 
to HDL efflux capacity suggesting a prominent role of the liver in the modulation of HDL quality. Out of these 
four acute phase proteins most research has been carried out with respect to SAA. In inflammatory states, plasma 
SAA is almost exclusively bound to the HDL fraction38,39. Previously, it was shown that enrichment of HDL with 
SAA decreases its cholesterol efflux properties18,40, which also translates into lower in vivo reverse cholesterol 
transport in a rodent model25. However, it should be noted that in a small-scale study in humans no impact of SAA 
on THP-1-mediated efflux towards HDL from T2DM patients has also been reported41. On the other hand, SAA 
has been linked to impairment of other key functions of HDL such as the protection against oxitative stress42 and 
inflammation43. Haptoglobin was shown to bind to apoA-I44 and has been suggested to be a modulator of RCT 
as well45. For ceruloplasmin it was shown that it is associated with the HDL fraction in inflammatory conditions, 
playing a role in inhibiting LDL oxidation46,47. This contrasts with the other hepatocyte-derived inflammation 
markers like hs-CRP for which no direct mechanistic role in modulating HDL function is appreciated. A poten-
tially important inflammatory biomarker, however, was not determined in the present study, namely myeloper-
oxidase. Myeloperoxidase-induced oxidative modifications of apoA-I have been shown to decrease cholesterol 
efflux and RCT48. Such a mechanism could conceivably contribute to the reduced efflux capacity in MetS patients.
Some potential limitations to this study should be considered. The chosen washout period for lipid lowering 
therapy was 14 days, which might not be sufficient to fully eliminate the effects of statins on lipoprotein metab-
olism. However, since patients with preexisting CVD were included, 14 days were considered the maximum 
period for safety reasons. In addition, a skewed lipoprotein profile, especially with high plasma triglycerides and 
low HDL-C levels was shown to affect influx of cholesterol into macrophages during efflux assays49, which is not 
accounted for by the methods employed in the present work or in previous studies by others dealing with choles-
terol efflux capacity and cardiovascular disease10,11. Further, due to the design of our study there is an unavoidable 
overlap between MetS and glucose tolerance categories. We took this into account by multivariable analysis with 
mutual statistical adjustments for the presence of either category, but it cannot be formally excluded that a certain 
effect remains.
In summary, our present study demonstrates in a large cohort of well characterized subjects that insulin resist-
ance and T2DM do not impact on cholesterol efflux, a key metric of HDL function. Rather, the presence of MetS 
translates into an impaired cholesterol efflux in close association with low HDL-C and apoA-I. Furthermore, we 
identified enhanced low-grade systemic inflammation as a relevant factor that may contribute to diminished HDL 
function independent of HDL-C and apoA-I levels specifically in the context of T2DM and MetS.
Patients and Methods
Study population and design. The study population consisted of participants of the Cohort on Diabetes 
and Atherosclerosis Maastricht (CODAM). This study includes 574 subjects selected from a large cohort in the 
general population (n > 20,000) on the basis of an elevated risk of type 2 diabetes mellitus and cardiovascular 
diseases as described in detail elsewhere35,50,51. Inclusion criteria comprised Caucasian origin and age above 40 
years, and, in addition, at least one of the following criteria: a positive family history of T2DM (first-degree 
relatives), BMI > 25 kg/m2, a history of gestational diabetes, use of anti-hypertensive medication, postprandial 
glucose ≥ 6.0 mmol/L, or glucosuria. All study participants were extensively characterized with regard to their 
lifestyle as well as their cardiovascular and metabolic profile during two visits to the University’s metabolic 
research unit. The study protocol was approved by the Medical Ethics Committee of the University of Maastricht 
and the Maastricht University Medical Center, and all subjects gave written informed consent. The described 
methods were carried out in accordance with the approved guidelines.
Height was measured with a stadiometer and weight with electronic weight scales with subjects wearing light 
indoor clothes without shoes. BMI was calculated as weight in kilograms divided by height in meters squared 
(kg/m2). Blood pressure was measured twice in supine position and on the right arm after a 5 min rest with an 
oscillometric precision blood pressure instrument (Maxi stable 3, Speidel & Keller). Waist circumference was 
measured in standing position at the level midway between the lateral lower rib margin and the spina iliaca ante-
rior superior.
The study subjects were asked to stop their lipid-modifying medication 14 days before and all other medica-
tion on the day before the visit to the University’s research unit (> 80% adherence). The participants underwent 
an oral glucose tolerance test (except those with established T2DM), and were then categorized as having NGM, 
IGM and T2DM. IGM was considered in case of either impaired glucose tolerance and/or impaired fasting glu-
cose levels50. Presence of the MetS was determined according to the National Cholesterol Education Program 
(NCEP) –Adult Treatment Panel (ATP) III definition as modified by the American Heart Association (AHA)/
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National Heart, Lung and Blood Institute (NHLBI)52. The exact distribution of the subjects over the different 
categories is given in Supplementary Table 3.
CVD was defined as self-reported myocardial infarction, coronary bypass surgery, percutaneous interven-
tions, stroke or transient ischemic attack (through questionnaires) and/or the presence of signs of myocardial 
infarction (Minnesota codes 1–1 or 1–2) or ischemia (Minnesota codes 1–3, 4–1, 4–2, 4–3, 5–1, 5–2, 5–3 or 7–1) 
on a 12-lead electrocardiogram or an ankle-brachial pressure index < 0.9 . For most of the cases (> 75% of the 
subjects with self-reported CVD), the self-reports could be confirmed using available hospital registries.
Smoking habits as well as the use of medication were also assessed by questionnaires. Alcohol consumption 
was estimated by a validated food frequency questionnaire53.
Laboratory measurements. Blood samples were obtained by venipuncture after an overnight fast. EDTA 
blood was collected in pre-cooled tubes on ice, centrifuged at 3000 rpm for 15 min at 4 °C. EDTA plasma and 
serum aliquots were stored at − 80 °C until use. Glucose was directly measured using routine procedures. Glycated 
hemoglobin (HbA1c) was determined by ion-exchange high-performance liquid chromatography (HPLC; 
Bio-Rad, Veenendaal, the Netherlands). Total cholesterol, HDL-cholesterol (HDL-C) and triglycerides were 
determined in EDTA plasma using the HDL-C plus assay, CHOD-PAP assay or the triglyceride GPO-PAP assay, 
respectively (Roche Diagnostics, Mannheim, Germany). LDL cholesterol was calculated with the Friedewald 
formula50. Plasma apoB and apoA-I were determined by immunonephelometric assays, using polyclonal rabbit 
anti-human apoB or apoA-I antiserum, and standards with the assigned values according to the International 
Federation of Clinical Chemistry (Behringwerke AG, Marburg, Germany)50.
Eight markers of low-grade inflammation were measured: hs-CRP, tumor necrosis factor-α (TNF-α ), 
interleukin-6 (IL-6), IL-8, SAA, soluble intercellular adhesion molecule 1 (sICAM-1), ceruloplasmin and hapto-
globin. The rationale for the specific selection of these markers and the respective assay systems used have been 
provided previously51. hs-CRP, IL-6, SAA and sICAM were measured by single biomarker techniques and with 
a multi-array (MA) detection system [Mesoscale Discovery, Rockville, MD USA]. The measures of the single 
biomarker techniques were realigned to the MA measures. IL-8 and TNF-α were determined in EDTA plasma 
using the MA detection system. Haptoglobin was measured in serum using the Tina-quant haptoglobin assay 
(Roche Diagnostics). Ceruloplasmin was measured with an immunoturbidimetric assay (Roche Diagnostics). A 
complete data set was available from 547 participants.
Determination of cholesterol efflux. HDL was isolated from EDTA plasma by precipitation of 
apoB-containing lipoproteins using polyethylene glycol (PEG 6000, Sigma, St Louis, MO) in 10 mM HEPES 
(pH = 8.0) as described previously10,42,54–57. Following 30 minutes centrifugation at 2200 g and 4 °C, the 
HDL-containing supernatant was transferred to a fresh tube and used the same day for cholesterol efflux 
measurements.
Cholesterol efflux capacity towards apoB-depleted plasma was studied using THP-1 human monocytes 
(ATTC via LGC Promochem, Teddington, UK) that were differentiated into macrophages by the addition of 
100 nM phorbol myristate acetate25,58. Differentiated THP-1 macrophages were then loaded with 50 μ g/ml 
acetylated LDL and 1 μ Ci/ml 3H-cholesterol (Perkin Elmer, Boston, MA) for 24 hours followed by equilibration 
for 24 hours in RPMI 1640 medium containing 2% bovine serum albumin25. After equilibration, efflux towards 
2% apoB-depleted plasma was performed for 5 hours. Following table-top centrifugation to pellet cell debris, an 
aliquot of medium was counted to quantitate the effluxed cholesterol label. Meanwhile the cells were incubated 
for at least 30 minutes with 0.1 M NaOH at room temperature, whereupon the radioactivity remaining within the 
cells was determined by liquid scintillation counting (Packard 1600CA Tri-Carb, Packard, Meriden, CT). Efflux 
per well is expressed as the percentage of counts released into the medium related to the total dose of radioactiv-
ity initially present (counts recovered within the medium added to the counts recovered from the cells). Values 
obtained from control cells without added apoB-depleted patient plasma were subtracted to correct for unspecific 
efflux.
Cholesterol efflux capacity measurements were carried out in all respective patient samples at the same time 
to limit potential variation due to different assay conditions. All measurements were performed in duplicate. 
To correct for potential plate-to-plate variation, the same apoB-depleted control plasma was included on each 
plate at four different concentrations and individual values were normalized to values obtained with a pool of 2% 
apoB-depleted control plasma using these respective standard curves. Thus values given for efflux do not have a 
specific unit. The intra-assay CV of this method is 5.4%, the interassay CV is 7.9%.
Statistical analysis. SPSS 22 was used for data analysis. Results are expressed as mean ± SD or as median 
(interquartile range). Because of skewed distribution logarithmically transformed values of triglycerides and 
hs-CRP, TNF-α , IL-6, IL-8, SAA, sICAM-1 were used. A low-grade inflammation score was computed by averag-
ing the Z-scores [(individual observed values − population mean)/population SD] of the 8 inflammation markers 
measured (hs-CRP, TNF-α , IL-6, IL-8, SAA, sICAM-1, ceruloplasmin and haptoglobin). The average value of 
the combined low grade inflammation score was used in the analyses. This composite score can be interpreted 
as eight repeated measurements of the same construct, i.e. inflammation, and thereby may reduce measurement 
errors. Moreover, the use of this inflammation score prevents multiple testing problems and is expected to reduce 
the influence of biological variability of each marker if assessed separately.
Differences in continuous variables among subjects with NGM, IGM and T2DM were determined by 
one-way analysis of variance (ANOVA) with subsequent Bonferroni method to correct for multiple compar-
isons. Differences between subjects with and without MetS were determined by Student T-tests for unpaired 
observations. Between-group differences in proportions were determined by Chi-square tests. Partial correlation 
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coefficients were calculated taking account of sex. Multivariable linear regression analyses were carried out to 
determine the independent contribution of variables to cholesterol efflux. Interaction terms were calculated as 
the product terms of glucose tolerance status or the presence of MetS with HDL cholesterol, apoA-I and the low 
grade inflammation score. For continuous variables distributions centered to the mean were made by subtracting 
the individual value of the variable of interest from their group mean values to account for outliers. Interaction 
terms were considered statistically significant at P-values < 0.10, as proposed by Selvin59 and recommended by 
the Food and Drug Administration authorities. Otherwise, two-sided P-values < 0.05 were considered significant.
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